UnknownPhase 2NCT03542851

A Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia

Studying Idiopathic hypersomnia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Balance Therapeutics
Principal Investigator
Morgan Lam
Chief Operating Officer
Intervention
Pentetrazol (PTZ)(drug)
Enrollment
80 target
Eligibility
18-70 years · All sexes
Timeline
20182020

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03542851 on ClinicalTrials.gov

Other trials for Idiopathic hypersomnia

Additional recruiting or active studies for the same condition.

See all trials for Idiopathic hypersomnia

← Back to all trials